0001104659-23-080008.txt : 20230711 0001104659-23-080008.hdr.sgml : 20230711 20230711164641 ACCESSION NUMBER: 0001104659-23-080008 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230710 FILED AS OF DATE: 20230711 DATE AS OF CHANGE: 20230711 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fahey Sandell Jacquelyn CENTRAL INDEX KEY: 0001984647 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37625 FILM NUMBER: 231082567 MAIL ADDRESS: STREET 1: C/O VOYAGER THERAPEUTICS, INC. STREET 2: 64 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Voyager Therapeutics, Inc. CENTRAL INDEX KEY: 0001640266 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 64 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-259-5340 MAIL ADDRESS: STREET 1: 64 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 tm2320946-3_4seq1.xml OWNERSHIP DOCUMENT X0407 4 2023-07-10 0 0001640266 Voyager Therapeutics, Inc. VYGR 0001984647 Fahey Sandell Jacquelyn C/O VOYAGER THERAPEUTICS, INC., 64 SIDNEY STREET CAMBRIDGE MA 02139 0 1 0 0 Chief Legal Officer 0 Stock Option (Right to Buy) 10.18 2023-07-10 4 A 0 122000 0 A 2033-07-10 Common Stock 122000 122000 D This stock option was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the "Company"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The vesting commencement date of the option is the grant date. The option vests over four years, with 1/4th of the shares of common stock underlying the option vesting upon the one-year anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service as an employee. /s/ Jacquelyn Fahey Sandell 2023-07-11